Business Wire India
A research team led by Professor Wang Wen-ching of the Institute of Molecular and Cellular Biology, National Ting Hua University (NTHU), has identified large data to identify two major biomarkers that contribute to the spread and metastasis of gastric (stomach) cancer. Exploited the power of. Using US Food and Drug Administration (FDA) -mediated drugs, the team conducted targeted therapies that could effectively eliminate tumor growth and prevent metastasis, paving the way for a new tailored therapy Can do. His research has been published in the latest issue Proceedings of the United States National Academy of Sciences.
This press release contains multimedia. Watch the full release here: https://www.businesswire.com/news/home/20201113005183/en/
Professor Wang Wen-ching (left) of the Institute of Molecular and Cellular Biology and Drs. Tseng Linglu is researching a new treatment for gastric cancer. (Photo: National Tussing Hua University)
Finding new ways to treat gastric cancer
Colon cancer is the fifth most common cancer worldwide, and has a high mortality rate because of its severe and difficult treatment for many patients. Wang said that it often happens that by the time someone is diagnosed, the cancer cells have already metastasized.
Wang stated that thus, there is only one target drug (his 2 therapies) that can treat gastric cancer, and is only suitable for less than 20% of patients worldwide. In Taiwan, this number falls to 8%. Wang’s team is working to reshape the mechanisms inherent in the proliferation of cancer cells and the discovery of new biomarkers, with the goal of developing a new tailored therapy.
Braking on stomach cancer
Wang reported that the major cause of proliferation of gastric cancer cells is the ineffectiveness of protein phosphatases and tannin homologs (PTEN), a tumor suppressor protein that acts like a brake. When the break fails, cancer cells will proliferate, expand and grow dangerous metastatic tumors. The team’s first task was to determine the basis for this “brake failure”.
The research team gathered information on more than 300 cases of gastric cancer and used big data to derive the biological pathway leading to cancer progression from over 30,000 potential genes. They revealed that the two enzymes PHF8 and PKCα play an important role in the puzzle. The nuclear enzyme PHF8 is prevalent in ~ 40% of gastric cancer tissue and causes PKCα to proliferate, leading to loss of PTEN, such as “break failure”.
Fortunately, PKCα activity can be inhibited by the drug midostaurin, an anti-cancer agent for the treatment of blood cancer approved by the US Food and Drug Administration three years ago. The team used zebrafish and mice models to provide proof-of-evidence that midostaurin treatment could reduce tumors and prevent further spread of cancer.
Wang stated that success in the search for an accurate therapy is through interdisciplinary collaboration. He is Dr. Grateful to Tseng Linglu, who earned a PhD with solid training in molecular medicine and biology at NTHU, Drs. Yeh-ta-sen, Director of the Department of General Surgery at Chang Goong Memorial Hospital in Linko, Drs. . Yu Chi Chou-hwa and Academia Sinica fellow Kung Hing-jien at the National Institute of Health Research.
The content is by Business Wire India. Tech Media is not responsible for the content provided or any link related to this content. Tech Media is not responsible for the accuracy, timeliness or quality of content.